Clinical Guides
Heavy Menstrual Bleeding
A source-grounded clinical guide to assessing and managing heavy menstrual bleeding, with an India-specific pathway, explicit safety limits and mandatory specialist review before publication.
MedNext Academy | 14 min read
Heavy Menstrual Bleeding
A source-grounded clinical guide to assessing and managing heavy menstrual bleeding, with an India-specific pathway, explicit safety limits and mandatory specialist review before publication.
Summary
Heavy menstrual bleeding is menstrual blood loss that a person experiences as excessive enough to interfere with physical, social, emotional or material quality of life. Modern practice does not require a measured volume before the problem is taken seriously. The clinical task is to determine whether the bleeding is acute or chronic, assess physiological impact such as anaemia, exclude pregnancy-related and non-uterine bleeding, identify a likely cause, and choose treatment that reflects symptoms, fertility goals, comorbidity and preference.
Causes are organised with the PALM-COEIN framework. PALM identifies structural causes: polyp, adenomyosis, leiomyoma, and malignancy or hyperplasia. COEIN identifies coagulopathy, ovulatory dysfunction, endometrial causes, iatrogenic causes and causes not otherwise classified. More than one contributor may coexist. The label heavy menstrual bleeding describes a symptom; it is not itself an aetiological diagnosis.
Initial assessment prioritises haemodynamic stability, pregnancy possibility, bleeding pattern, pain or pressure symptoms, medicines, bleeding history and effect on daily life. A full blood count is appropriate for everyone presenting with HMB. Examination and imaging are selected according to associated symptoms and the proposed treatment rather than ordered as an indiscriminate panel. Medical treatment is usually first-line when the person is stable and cancer or a major structural lesion is not suspected. The levonorgestrel-releasing intrauterine system, tranexamic acid, non-steroidal anti-inflammatory drugs, combined hormonal contraception and selected progestogen regimens are possible options in appropriate patients. Procedures are cause-directed. This educational draft is not a prescription and has been reviewed by the MedNext Clinical Team.
How Common Is It?
Heavy menstrual bleeding is a common presentation across adolescence, the reproductive years and perimenopause, but a single prevalence percentage is misleading. Studies use different questions, age ranges, laboratory definitions and cultural assumptions; measured blood loss and lived burden also do not always agree. current guidelines therefore centres the diagnosis on quality-of-life impact rather than demanding an 80 mL threshold in routine care. A person who changes activities, misses school or work, avoids travel, wakes repeatedly to change protection, or experiences flooding and leakage may have clinically important HMB even without a formal volume measurement.
The burden includes fatigue, reduced exercise tolerance, impaired concentration, sleep disruption, anxiety about leakage, sexual or social restriction and iron-deficiency anaemia. Access to menstrual products, toilets and private washing facilities influences how much the same bleeding pattern disrupts life. Apparent prevalence can therefore change with survey wording and setting. Indian clinic populations should not be extrapolated to the whole country, and this guide does not claim a national rate.
Age changes the differential more than it changes the need to listen. Early after menarche, anovulation is common, but bleeding from the first periods plus bruising, epistaxis, gum bleeding or a family history raises concern for a bleeding disorder. During reproductive years, pregnancy-related causes must be excluded when possible. In perimenopause, ovulatory disturbance and fibroids may be more frequent, but endometrial pathology must not be missed. The useful epidemiological lesson is that HMB is common and consequential, while individual severity and cause still require assessment.
Risk Factors
Risk factors should be linked to plausible causes rather than treated as proof. A history of heavy bleeding since menarche, recurrent epistaxis, easy bruising, gum bleeding, excessive bleeding after dental work or surgery, postpartum haemorrhage, or a family history of abnormal bleeding increases suspicion for an inherited or acquired coagulopathy. Anticoagulants and medicines that alter platelet function can worsen bleeding, but stopping them without assessing the indication may be dangerous.
Structural disease is more likely with an enlarged or irregular uterus, pressure symptoms, subfertility, progressive dysmenorrhoea, intermenstrual bleeding or a previously identified fibroid, adenomyosis or polyp. Endometrial hyperplasia risk rises with prolonged unopposed oestrogen exposure, including chronic anovulation associated with polycystic ovary syndrome, obesity and some endocrine disorders. Age alone does not diagnose malignancy, but it affects the threshold for endometrial evaluation when bleeding is persistent or atypical.
Ovulatory dysfunction may accompany adolescence, perimenopause, thyroid disease, hyperprolactinaemia, substantial weight change, energy deficit or systemic illness. Pregnancy and complications of pregnancy remain possible whenever conception can occur. Copper intrauterine devices can increase menstrual loss; hormonal methods may produce irregular bleeding, especially after initiation, but new or persistent symptoms still require review.
Risk assessment must also cover consequences. Limited dietary iron, previous anaemia, gastrointestinal malabsorption, close pregnancies and restricted access to care can increase vulnerability to iron deficiency. A risk factor changes the questions, examination or investigations; it should never be used to dismiss the patient's account or to assign a cause without evidence.
Diagnosis
Heavy menstrual bleeding is diagnosed clinically from the bleeding history and its effect, while the cause and physiological consequences are assessed separately. First decide whether this is acute bleeding needing immediate intervention, chronic HMB, or chronic HMB with an acute deterioration. Record pulse, blood pressure, symptoms of hypovolaemia and anaemia, and pregnancy possibility before pursuing a routine outpatient pathway.
History
Clarify cycle frequency and regularity, duration of flow, flooding, clots, night changes, double protection, leakage and change from the person's baseline. Ask about intermenstrual or postcoital bleeding, pelvic pain, pressure, dyspareunia, discharge and fertility goals. Document fatigue, breathlessness, dizziness, school or work absence and product access. Establish the date of the last menstrual period and test for pregnancy when possible. Ask about bleeding since menarche, bruising, epistaxis, dental or surgical bleeding and family history. Review contraception, anticoagulants, endocrine symptoms, chronic disease, prior treatment and cervical-screening history.
Examination
Assess pallor, pulse, blood pressure, hydration and signs of haemodynamic compromise. Abdominal examination looks for tenderness or a mass. Pelvic examination is appropriate when there are associated symptoms, before an intrauterine system or relevant investigation, or when cervical, vaginal, uterine or adnexal disease is possible; obtain consent, explain each step and offer a chaperone. It may be deferred in uncomplicated HMB when pharmacological treatment is appropriate and no examination-dependent intervention is planned, consistent with current guidelines.
Investigations
Obtain a full blood count for all patients. Add a pregnancy test whenever pregnancy is possible. Coagulation testing and haematology-directed von Willebrand assessment are targeted to a positive bleeding history; normal screening tests do not exclude every disorder. Do not order female hormones routinely, and test thyroid function only when symptoms or examination suggest thyroid disease under current guidelines guidance. Choose hysteroscopy or pelvic ultrasound according to history and examination. Current guidelines favours outpatient hysteroscopy when submucosal fibroids, polyps or endometrial pathology are suspected, and ultrasound when a larger fibroid, pelvic mass or adenomyosis is suspected or examination is difficult. Endometrial sampling is risk-directed and should not be performed blindly as a universal test.
Differential Diagnosis
Use PALM-COEIN after excluding pregnancy-related and non-uterine bleeding. Polyps can cause intermenstrual or heavy bleeding and are assessed within the uterine cavity. Adenomyosis commonly combines HMB with progressive dysmenorrhoea and a tender or bulky uterus. Leiomyomas vary by size and location; submucosal lesions can produce substantial bleeding even when the overall uterus is not very large. Endometrial hyperplasia or malignancy becomes more concerning with persistent irregular or intermenstrual bleeding, prolonged anovulation, relevant metabolic risk, abnormal examination or treatment failure.
Coagulopathy is especially important when HMB began at menarche or accompanies mucocutaneous or procedure-related bleeding. Ovulatory dysfunction often produces irregular, unpredictable or prolonged episodes and can accompany adolescence, perimenopause, PCOS, thyroid or prolactin disorders, major weight change and systemic illness. An endometrial cause is considered when ovulation appears regular and structural or systemic causes are not found. Iatrogenic causes include copper intrauterine contraception, anticoagulants and several hormonal regimens. Rare causes include uterine arteriovenous malformation and caesarean-scar niche.
Do not overlook miscarriage, ectopic pregnancy or gestational trophoblastic disease in someone who could be pregnant. Cervical disease, cervicitis, vaginal trauma, vulval lesions, haematuria and rectal bleeding may be described as heavy periods until the source is clarified. Infection is suggested by fever, discharge and pelvic tenderness rather than bleeding alone.
The differential is not a checklist to complete mechanically. Use chronology, examination and targeted testing to identify the most likely contributors, allow coexistence, and revisit the formulation if treatment fails or the pattern changes.
Management
Stabilise acute haemodynamic compromise before diagnostic completeness. Establish intravenous access, obtain urgent blood count, pregnancy testing and cross-match as clinically indicated, correct shock and involve gynaecology or emergency services. The cause, severity, thrombotic risk, contraindications and fertility wishes determine acute medical or procedural treatment. This guide deliberately does not provide an unsupervised acute dosing protocol.
For stable chronic HMB, agree goals: less bleeding, improved function, correction of anaemia, pain relief, contraception, fertility preservation or definitive treatment. Treat iron deficiency and investigate its cause while controlling menstrual loss. When there is no identified pathology, a cavity not distorted by fibroids smaller than 3 cm, or suspected adenomyosis, current guidelines recommends considering an LNG-IUS first. Explain that bleeding may be irregular initially and that benefit may take several cycles.
If an LNG-IUS is declined or unsuitable, consider tranexamic acid or an NSAID during menstruation, or an appropriate hormonal option such as combined hormonal contraception or cyclical oral progestogen. Selection depends on pregnancy intention, thrombotic and cardiovascular risk, migraine, renal and gastrointestinal disease, concurrent medicines and acceptability. Persistent symptoms require a review of adherence, diagnosis and treatment goal rather than indefinite repetition.
Management of polyps, fibroids, adenomyosis, hyperplasia, malignancy or coagulopathy is cause-directed. Options can include hysteroscopic removal, myomectomy, uterine artery embolisation, endometrial ablation or hysterectomy, each with distinct fertility and risk implications. Hysterectomy is not a routine first step for uncomplicated HMB. Discuss alternatives, complications, recovery, ovarian function and loss of fertility. Shared decision-making is essential because similar bleeding can justify different choices for different patients.
Prescribing Information
This section is a safety framework, not an individual prescription. Before treatment, verify pregnancy status where relevant, haemodynamic stability, likely cause, current haemoglobin, medicine list, allergies, renal and liver function when indicated, thrombotic risk, migraine history, gastrointestinal disease, bleeding disorder, contraception needs and fertility intention. Use current Indian product information and local protocols; formulation availability and licensed indications can change.
Tranexamic acid is taken only during bleeding in most chronic HMB regimens. Avoid or seek specialist advice when active or previous thromboembolic disease, significant renal impairment or interacting procoagulant treatment makes use unsafe; adjust for renal function according to the current label. Sudden visual symptoms, chest pain, acute breathlessness or unilateral leg swelling require urgent assessment. Do not combine products casually or exceed the verified regimen because bleeding remains heavy.
NSAIDs can reduce both menstrual loss and dysmenorrhoea when ovulatory bleeding is present. They can cause gastrointestinal injury, renal dysfunction, fluid retention or hypersensitivity and may be unsuitable with peptic ulcer disease, renal impairment, some asthma phenotypes, anticoagulation or platelet dysfunction. Avoid them as a default treatment for suspected coagulopathy without haematology advice.
Combined hormonal contraception requires a structured eligibility check for venous thromboembolism, smoking and age, migraine with aura, hypertension, cardiovascular disease, liver disease, breast cancer and interacting medicines. Progestogen and LNG-IUS options have different bleeding patterns and contraindications; insertion requires pregnancy exclusion, consent and infection or cavity assessment when indicated. Treat iron deficiency with a verified elemental-iron plan and reassess response. Prescribing should always include a review date, expected benefit, adverse-effect advice and a clear plan if bleeding worsens.
When to Refer
Refer immediately to emergency or gynaecology services when bleeding causes haemodynamic instability, syncope, ongoing flooding with deterioration, severe symptomatic anaemia, suspected ectopic pregnancy or miscarriage, peritonism, sepsis, a rapidly enlarging painful mass, or inability to maintain outpatient safety. Stabilisation and local major-haemorrhage pathways take priority over completing a routine HMB work-up.
Arrange prompt specialist assessment for persistent intermenstrual or postcoital bleeding, suspected cervical or endometrial malignancy, an abnormal cervix, significant cavity pathology, a pelvic mass, or abnormal imaging. Refer for hysteroscopy when the history suggests a polyp, submucosal fibroid or endometrial pathology. Involve haematology when the structured bleeding history is positive, HMB began at menarche, laboratory findings suggest a coagulation disorder, or bleeding remains unexplained and severe.
Planned gynaecology referral is appropriate when first-line treatment is ineffective, not tolerated or contraindicated; symptoms remain life-limiting; a fibroid is 3 cm or larger; adenomyosis is uncertain or refractory; fertility could be affected; or the patient wants to discuss procedural options. Adolescents with complex bleeding, severe anaemia or possible structural disease benefit from an age-appropriate gynaecology service.
A useful referral contains the exact bleeding pattern, pregnancy result where relevant, haemodynamic observations, full blood count and iron status if obtained, bleeding-disorder screen, examination findings, imaging, prior treatments and response, medical risks and the patient's fertility and treatment priorities. Referral should accelerate a decision, not simply transfer an undocumented problem.
Red Flags
Acute red flags are collapse, syncope, confusion, chest pain, breathlessness at rest, marked tachycardia, hypotension, orthostatic symptoms, pallor with functional compromise, rapidly soaking protection, uncontrolled bleeding or severe pain. These features require urgent assessment even if previous periods were heavy. A positive or possible pregnancy with pain, shoulder-tip pain, dizziness or bleeding is an ectopic-pregnancy pathway until safely excluded.
Cancer-related warning features include persistent intermenstrual or postcoital bleeding, a visibly abnormal cervix, new bleeding after menopause, unexplained weight loss, a pelvic mass, offensive discharge or persistent symptoms despite reasonable treatment. They do not diagnose cancer, but they lower the threshold for examination, imaging, hysteroscopy, biopsy or referral. Do not suppress unexplained bleeding indefinitely with repeated hormonal prescriptions.
Bleeding-disorder red flags include HMB from menarche plus recurrent epistaxis, gum bleeding, easy bruising, postpartum haemorrhage, excessive surgical or dental bleeding, or affected relatives. Severe headache, neurological symptoms or visual change while using a haemostatic or hormonal medicine requires urgent review. Chest pain, acute breathlessness and unilateral leg swelling raise concern for thromboembolism.
Infection or acute abdominal signs also redirect care: fever, toxic appearance, purulent discharge, cervical excitation, guarding, rebound, vomiting or a tender mass. Safety-net every patient with instructions about where to seek help, because the number of pads used alone cannot reliably determine physiological severity.
Indian Clinical Context
India now has a 2026 FOGSI-affiliated good clinical practice recommendation for abnormal uterine bleeding, published in an Indian peer-reviewed journal. It supports PALM-COEIN classification, structured history for coagulopathy, full blood count, pregnancy testing when indicated, targeted imaging, first-line medical treatment and cause-directed procedures. It also states that parts of the evidence base are international and that some recommendations rely on expert consensus. This guide therefore treats it as professional guidance, not a statutory national standard.
Access differs sharply between community clinics, district hospitals and tertiary centres. A safe minimum pathway is possible in most settings: assess stability, establish pregnancy possibility, obtain a full blood count, take a structured bleeding and medicine history, examine when indicated, start an appropriate reversible treatment for a stable patient, and document a referral threshold. Limited access to hysteroscopy, specialist ultrasonography, von Willebrand testing, LNG-IUS insertion or surgery should be stated in the plan rather than hidden by diagnostic certainty.
Affordability, menstrual stigma, school attendance, work without reliable toilet access and the cost of products or transport affect treatment choice. Ask what outcome matters to the patient and avoid assuming that contraception, amenorrhoea, fertility preservation or surgery is acceptable. Use generic names and verify current Indian labels and availability. Do not recommend locally marketed herbal, haemostatic or hormonal products without a reliable evidence and safety review.
No national prevalence estimate is asserted here. The NMC curriculum supplies the educational requirement, while clinical choices require current local protocols and specialist judgement. Teleconsultation can support follow-up but cannot replace examination for instability, a mass, abnormal cervix or suspected malignancy.
NMC Competency Mapping
The National Medical Commission CBME Curriculum 2024 maps this topic most directly to Obstetrics and Gynaecology competency OG24.1: the learner should define, classify and discuss abnormal uterine bleeding, including aetiology, clinical features, investigations, diagnosis and management. HMB is a symptom within AUB, so a competent answer begins by defining the symptom, then classifies possible causes with PALM-COEIN rather than using the obsolete label dysfunctional uterine bleeding as a final diagnosis.
At the Know level, learners should describe structural and non-structural categories, recognise anaemia and state that quality-of-life impact matters. At Know How level, they should distinguish acute instability from stable chronic HMB, choose a focused history and examination, request a full blood count and pregnancy test where relevant, identify when coagulation assessment, ultrasound, hysteroscopy or endometrial sampling is appropriate, and explain why tests are targeted.
At Show How level, learners can take a respectful menstrual and bleeding history, assess haemodynamic observations, explain pelvic examination and obtain consent, interpret a blood count, counsel about first-line options and provide safety-netting in a simulated or supervised setting. Prescribing, intrauterine-system insertion, biopsy and procedural decisions require supervision and local policy.
This mapping also integrates physiology of the menstrual cycle, pathology of endometrium and myometrium, pharmacology of antifibrinolytics, NSAIDs and hormones, haematology of inherited bleeding disorders, and communication about fertility. The guide does not invent a separate HMB competency code. Formal course mapping should use the current institutional NMC ledger and preserve OG24.1 as the cited anchor.
Key Exam Pearls for NEET PG
Heavy menstrual bleeding is a symptom defined by adverse effect on quality of life, not merely a measured loss above a fixed volume. Start an answer by assessing stability and pregnancy possibility. A full blood count is routine; female hormone testing is not. Thyroid testing is targeted under current guidelines guidance, while Indian professional recommendations may use broader testing, so state the jurisdiction and clinical indication.
Use PALM-COEIN: polyp, adenomyosis, leiomyoma, malignancy or hyperplasia; coagulopathy, ovulatory dysfunction, endometrial, iatrogenic and not otherwise classified. PALM causes are structural and usually assessed by imaging or histopathology; COEIN causes are non-structural. More than one cause can coexist. HMB from menarche with mucocutaneous or procedure-related bleeding should trigger a coagulopathy history and haematology-directed testing.
Choose investigations from the presentation. Hysteroscopy is preferred when an intracavitary lesion or endometrial pathology is suspected; ultrasound is useful for a pelvic mass, larger fibroids or adenomyosis. A blind biopsy is not the universal first test. Persistent intermenstrual or postcoital bleeding, risk of unopposed oestrogen, treatment failure or a suspicious examination changes the threshold for endometrial assessment.
For stable HMB without major cavity distortion, LNG-IUS is an important first option when acceptable. Alternatives include tranexamic acid, NSAIDs, combined hormonal contraception and cyclical oral progestogen in suitable patients. Match treatment to cause, contraindications and fertility goals. Endometrial ablation is incompatible with future pregnancy; hysterectomy is definitive but major. In an emergency, resuscitation and urgent specialist care come before memorising a drug regimen.
Frequently Asked Questions
How can someone tell whether menstrual bleeding is clinically heavy?
The practical definition is bleeding that interferes with physical, social, emotional or material quality of life. Flooding, leakage, repeated night changes, avoiding activities, missing school or work, fatigue or anaemia all matter. Counting pads is imprecise because products and changing habits vary. A clinician should still ask about duration, regularity, clots, associated pain, pregnancy possibility and symptoms of circulatory compromise.
Which initial blood test is expected for heavy menstrual bleeding?
A full blood count is recommended for everyone with HMB to assess anaemia and platelet count. Pregnancy testing is added whenever pregnancy is possible. Coagulation and von Willebrand testing are targeted to a suggestive bleeding history, usually with haematology input. Female hormone tests are not routine, and thyroid testing should follow symptoms, examination and the applicable local guideline rather than be ordered automatically.
Is surgery always needed when fibroids cause heavy bleeding?
No. Management depends on fibroid size, number and location, symptom severity, anaemia, cavity distortion, age, fertility goals and previous response. Medicines or an LNG-IUS may be suitable for some patients, while submucosal or larger symptomatic fibroids may need hysteroscopic removal, myomectomy, embolisation or another procedure. Hysterectomy is definitive but should follow a full discussion of alternatives and consequences.
When does heavy menstrual bleeding require emergency care?
Seek urgent care for collapse, fainting, confusion, breathlessness at rest, chest pain, severe dizziness, marked weakness, rapidly continuing bleeding, severe pelvic pain, fever or a possible pregnancy with pain or bleeding. These features can indicate haemodynamic compromise, severe anaemia, ectopic pregnancy, miscarriage, infection or another acute condition. Do not wait for a routine appointment or rely only on the number of pads used.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic